Publications by authors named "A Cournil"
Vaccination against the COVID-19 virus is currently the best option to combat the SARS-CoV-2 pandemic worldwide. However, in addition to logistical and economic barriers, hesitancy to be vaccinated threatens to jeopardize efforts to contain the disease. An increasing number of people in Africa are delaying or rejecting recommended vaccines.
View Article and Find Full Text PDFIntroduction: G1 and G2 alleles have been associated with kidney-related outcomes in people living with HIV (PLHIV) of Black African origin. No APOL1-related kidney risk data have yet been reported in PLHIV in West Africa, where high allele frequencies have been observed.
Methods: We collected clinical data from PLHIV followed in Burkina Faso ( = 413) and in the ANRS-12169/2LADY trial (Cameroon, Senegal, Burkina Faso, = 369).
Objective: To estimate the residual mortality rate among people who inject drugs (PWID) in a Low-Middle Income Countries context where the HIV epidemic has been controlled and methadone coverage is high.
Study Design And Setting: PWID from Haiphong, Vietnam, were recruited through three annual respondent-driven sampling surveys that fueled two cohorts of PWID with HIV (n = 761) and without HIV (n = 897), with bi-annual follow-up. Presumed causes of death were ascertained from medical records and/or interviews of participants family.
Background: Syphilis is endemic in the Sub-Saharan zone and disproportionately affects at-risk populations such as men who have sex with men, sex workers and HIV infected individuals. In this study, we measure the impact of syphilis among people living with HIV in the Republic of Chad, where no data are currently available.
Method: Outpatients attending 2 HIV clinics in N'Djamena, Republic of Chad, were tested for syphilis.
Article Synopsis
- The ANRS 12174 trial compared growth and outcomes in HIV-exposed uninfected African neonates treated with lopinavir-ritonavir (LPV/r) vs. lamivudine (3TC) for a year.
- A follow-up study evaluated 553 out of 1101 eligible children, aged 5-7 who were not HIV-infected, focusing on growth and neuropsychological outcomes.
- Results showed no significant differences between the LPV/r and 3TC groups in growth or neuropsychological outcomes, indicating no long-term side effects from LPV/r treatment.